Tag Archives: PD

November, 2017

20 November
Acorda Discontinues Development of its Late-Stage Parkinson’s Disease Drug due to Safety Concerns

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it is discontinuing its clinical development program for tozadenant, an investigational treatment for Parkinson’s disease, including immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies. The Company made this decision based on new information obtained from the Phase …
Share
15 November
Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc.(Nasdaq:ACOR) today announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease. The Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated …
Share

25 August
FDA Approves Adamas’ Gocovri for the Treatment of Dyskinesia in Parkinson’s Disease Patients

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI, previously granted orphan drug status by …
Share

22 March
FDA Approves Newron’s Xadago for Treatment of Patients with Parkinson’s Disease

Milan, Italy and Morristown, NJ, U.S.A., – March 21, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced today …
Share

13 February
Acorda Therapeutics’ Inhaled Drug Successfully Reduces Parkinson’s Disease Symptoms in Late-Stage Study

ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods …
Share

23 March
The Hepatitis C-Parkinson’s Disease Link

An estimated 3.5 million Americans have chronic hepatitis C virus (HCV) infection, a contagious liver disease that can lead to cirrhosis and/or liver cancer. Meanwhile, an estimated one million Americans live with the progressive movement disorder of Parkinson’s disease. For the first time, research indicates that these two conditions could …
Share